Read the 2005 Newsletters and recent scientific references 2005, issue 1: IB4-SAP Prevents Axotomy-Induced Sprouting of Aß Fibers / by Pearson M / featuring IB4-SAP (Cat. #IT-10) ATS Seeks Strategic Partner for Chronic Pain Drug SFN Poster of the Year Targeting Talk: Effective Toxins Targeting Tools: Anti-ChAT (Cat. #AB-N34 and AB-N34AP) 2005, issue 2: Noradrenergic inputs to […]
Targeting Trends 2005 Newsletter Read More »
ATS is pleased to present a polyclonal antibody specific for ChAT protein. Choline acetyltransferase (ChAT) catalyzes the synthesis of the neurotransmitter acetylcholine (ACh) from choline and acetyl-CoA in cholinergic neurons. ChAT serves as a specific marker for cholinergic neurons in both the peripheral and central nervous systems. Dysfunction of cholinergic neurons underlies aspects of clinical
Targeting Tools: Anti-ChAT Read More »
Toxicology studies with the potential chronic pain therapeutic, SP-SAP (Substance P-Saporin) are continuing successfully. The second study will be initiated in a few months and ATS is diligently pursuing a pharmaceutical partner that can quickly bring the drug to clinical trials in humans. With the recent news of the undesirable side effects of such pain
ATS Seeks Strategic Partner for Chronic Pain Drug Read More »
Contributed by ATS’s 2004 Society for Neuroscience Poster of the Year Award Winner:Michelle Pearson, Purdue Pharma, Discovery Research, 6 Cedar Brook Drive, Cranbury NJ 08540 Neuropathic pain results in hyperalgesia and allodynia. It has been proposed that sprouting of myelinated touch-responsive Aβ-fibers into the innervation territory of pain-sensitive C-fibers in the spinal cord contributes to
Cover Article: IB4-SAP Prevents Axotomy-Induced Sprouting of Aß Fibers Read More »